Diagnostics meets therapeutics: the impact of pharmacogenetics

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.

Communications medicine·2026

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

The Lancet regional health. Western Pacific·2026

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Lancet (London, England)·2026

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

European journal of cancer (Oxford, England : 1990)·2025

Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.

The Lancet. Haematology·2025

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.

The Lancet. Haematology·2024

Organoids and organ-on-a-chip platforms for advancing oligonucleotide drug development.

Drug discovery today·2026

Integrating population heterogeneity in drug research and early development: a proactive strategy.

Drug discovery today·2026

Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.

Drug discovery today·2026

Artificial intelligence (AI)-enabled platforms for cancer vaccine engineering.

Drug discovery today·2026

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Drug discovery today·2026

Signaling execution readiness: The evolving leadership requirements for biotech fundraising.

Drug discovery today·2026

[Anatomical variations of peripancreatic veins and surgical strategies].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026

M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026

Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.

International journal of pharmaceutics·2026

Clinical Implementation of Pharmacogenetics-Based Machine Learning Clinical Decision Support Systems: A Scoping Review.

Applied clinical informatics·2026

Substance use-related stigma and injection-related bacterial infections among people who inject drugs in Montreal.

The International journal on drug policy·2026

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States.

Current medical research and opinion·2026

Related Experiment Videos

Diagnostics meets therapeutics: the impact of pharmacogenetics

Related Concept Videos

Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.

Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.

Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.

Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).

Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.

Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.

Organoids and organ-on-a-chip platforms for advancing oligonucleotide drug development.

Integrating population heterogeneity in drug research and early development: a proactive strategy.

Metabolic reprogramming and drug resistance in hepatocellular carcinoma: The emerging role of SREBP2-driven cholesterol metabolism.

Artificial intelligence (AI)-enabled platforms for cancer vaccine engineering.

GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals.

Signaling execution readiness: The evolving leadership requirements for biotech fundraising.

[Anatomical variations of peripancreatic veins and surgical strategies].

M4 drug discovery: Human drug predictions from integrated preclinical insights exemplified with a GLP-1R agonist.

Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: formulation development, characterization and biological evaluation.

Clinical Implementation of Pharmacogenetics-Based Machine Learning Clinical Decision Support Systems: A Scoping Review.

Substance use-related stigma and injection-related bacterial infections among people who inject drugs in Montreal.

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States.

Related Experiment Videos

Diagnostics meets therapeutics: the impact of pharmacogenetics

Related Concept Videos

Related Articles